SGMT Latest Press Releases

-- October 29, 2026 --

Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:00 AM

-- October 22, 2026 --

Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne Globe Newswire 7:00 AM

-- October 9, 2026 --

Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference Globe Newswire 7:00 AM

-- October 1, 2026 --

Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants Globe Newswire 4:31 PM

-- September 30, 2026 --

Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants Globe Newswire 6:19 AM

Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026 Globe Newswire 6:00 AM

-- September 28, 2026 --

Sagimet Biosciences to Host Virtual KOL Event, 'Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US' on September 30, 2026 Globe Newswire 7:00 AM

-- September 2, 2026 --

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences Globe Newswire 7:00 AM

-- August 25, 2026 --

Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026 Globe Newswire 7:00 AM

-- August 17, 2026 --

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:28 PM

-- August 13, 2026 --

Sagimet Biosciences Receives FDA 'Study May Proceed' Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients Globe Newswire 7:00 AM

-- August 11, 2026 --

Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Globe Newswire 7:30 AM

-- August 4, 2026 --

Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference Globe Newswire 7:00 AM

-- June 29, 2026 --

Sagimet Biosciences Joins the Russell 2000 and Russell 3000 Indexes Globe Newswire 7:00 AM

-- June 22, 2026 --

Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 8:49 PM

Market Data Delayed 15 Minutes